B cell responses in SLE are currently hampered by two main means i.e., (i) BAFF inhibition through belimumab, and (ii) B cell depletion through anti-CD20 agents, such as rituximab, obinutuzumab, and ofatumumab. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.